Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation

Title:Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation

Volume: 22 Issue: 16

Author(s): Sara Mongiorgi, Matilde Y. Follo, Yong Ryoul Yang, Stefano Ratti, Lucia Manzoli, James A. McCubrey, Anna Maria Billi, Pann-Ghill Suh and Lucio Cocco

Affiliation:

Keywords: PI-PLCbeta1, Nucleus, Cell Cycle, Differentiation, Hematopoiesis, MDS.

Abstract: Nuclear phosphoinositide-phospholipase C (PI-PLC) beta1 plays a crucial role in the molecular steps that regulate cell proliferation and differentiation in several experimental models, such as myoblasts and hematopoietic cells, via interaction with other important molecular players. Indeed, PI-PLCbeta1 and its related molecules are definitely involved in hematopoiesis, and particularly in drug-induced myeloid or erythroid differentiation. Here, we review the role of nuclear PI-PLCbeta1 signalling in normal hematopoiesis, in pathogenesis and in drug-related induction of hematopoietic differentiation, with particular reference to the current therapy of Myelodysplastic Syndromes (MDS).

Cite this article as:

Mongiorgi Sara, Y. Follo Matilde, Ryoul Yang Yong, Ratti Stefano, Manzoli Lucia, A. McCubrey James, Maria Billi Anna, Suh Pann-Ghill and Cocco Lucio, Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation, Current Pharmaceutical Design 2016; 22 (16) . https://dx.doi.org/10.2174/1381612822666160226132338